Updated Pick,five approved ACPs named Tebentafusp, Buserelin, Plitidepsin, Triptorelin, and Dactinomycin

The year 2022 marked a significant period for advancements in peptide therapeutics, with the FDA granting its approval to several key peptides and oligonucleotides. Understanding these FDA approved peptides 2022 developments is crucial for researchers, healthcare professionals, and patients alike, as it signifies progress in treating a variety of conditions. The regulatory body's rigorous evaluation process ensures that these peptide-based drugs meet stringent safety and efficacy standards before reaching the market.

In 2022, a notable number of therapeutic agents, specifically pepTIDEs and oligonucleotides, received the FDA approved seal of recognition. Research indicates that a total of five TIDES (four peptides and one oligonucleotide) were authorized by the United States Food and Drug Administration (FDA) in 2022. This influx of approved therapies reflects the growing understanding and application of peptide science in modern medicine. The FDA's role in this process is paramount, as it ensures that only FDA approved treatments are made available for public use, safeguarding patient well-being.

Among the significant FDA approved peptides 2022 designations, several stand out. For instance, Tirzepatide, Lutetium 177Lu Vipivotide Tetraxetan, and Terlipressin were among the peptide drugs approved in the latter half of the year. Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has shown promise in managing type 2 diabetes and obesity. Lutetium 177Lu Vipivotide Tetraxetan is a radioligand therapy used for treating prostate cancer, while Terlipressin is employed to manage a specific type of low blood pressure.

Beyond these specific examples, the FDA's historical data reveals a consistent interest in peptide therapeutics. Since 1923, the FDA has approved approximately ten natural peptides for various indications, with a substantial number, nine peptides, specifically for diabetes management. Furthermore, four growth hormone-releasing hormones have also received approval over the years, highlighting the diverse therapeutic applications of peptides. The journey of peptide drug development is an ongoing one, and the FDA's oversight ensures that each new approved therapy contributes meaningfully to patient care.

The FDA's approval process is not limited to a single year. Looking at broader trends, in 2021, the FDA approved a substantial pipeline of fifty drugs, which included eight peptides, two oligonucleotides, and two ADCs (antibody-drug conjugates) containing peptides. This demonstrates a sustained and growing interest in peptide and oligonucleotide technologies. Similarly, in 2023, various structural peptides were approved, encompassing linear, cyclic, and lipopeptides, further solidifying the presence of peptides in the pharmaceutical landscape.

It is important to note that while many peptides are being researched and utilized, the critical distinction lies in their regulatory status. As of recent updates, some peptides that may have been available for compounding in the past have undergone reclassification or are no longer approved for such use by the FDA. For example, Ipamorelin, once considered one of the safer GH-releasing peptides with minimal side effects, has been noted for changes in its approval status. This underscores the importance of verifying the FDA approved status of any peptide for medical or therapeutic purposes.

The FDA's commitment to advancing medical treatments is evident in the continuous review and approval of novel therapies. In 2024, the FDA's Center for Drug Evaluation and Research (CDER) approved fifty new molecular entities (NMEs), which included four peptides and oligonucleotides (two pepTIDEs and two oligonucleoTIDEs). This ongoing innovation suggests a promising future for peptide-based medicine. The agency also approves drugs for rare diseases and oncology, as seen with the approvals of Oxlumo and Pepaxto in 2021, which may include peptide components or targets.

The complexity of peptide approvals is further illustrated by the fact that some peptides do have FDA approval for specific medical indications. This means that not all peptides are broadly approved for general use, but rather for targeted therapeutic applications. For instance, there are five approved ACPs (Anti-Cancer Peptides) named Tebentafusp, Buserelin, Plitidepsin, Triptorelin, and Dactinomycin, with several others currently undergoing clinical trials. This targeted approach ensures that the benefits of peptide therapies are maximized for the patients who need them most.

In conclusion, 2022 represented a significant